Renal Anhydramnios Fetal Therapy (RAFT) Trial

Description

Early pregnancy renal anhydramnios or EPRA is a condition where a pregnant woman does not have any amniotic fluid around her fetus because of a problem with the fetus's kidneys. This condition is thought to be fatal once the fetus is born because of inadequate lung growth. The Renal Anhydramnios Fetal Therapy (RAFT) Trial offers eligible pregnant women with a diagnosis of EPRA an experimental therapy of repeated or serial "amnioinfusions" of fluid into the womb. An amnioinfusion involves placing a small needle through the pregnant woman's skin into the womb next to the fetus. Warm sterile fluid with balanced electrolytes and antibiotics is then slowly infused into amniotic space inside the womb. The aim is to help the fetus's lungs grow enough so he or she can survive after birth. These amnioinfusions will be carried out by an expert in fetal interventions at a RAFT center. There is a significant risk of early rupture of membranes and early delivery in subjects who receive amnioinfusio

Trial Eligibility

Inclusion Criteria: 1. Confirmed anhydramnios before 22 weeks GA for patients with fetal renal failure (excluding bilateral renal agenesis) 2. Consent is signed and first therapeutic amnioinfusion can and does occur before 26 weeks and 0 days GA 3. Confirmation that the expectant mother does not wish to undergo termination of the pregnancy 4. Age ≥ 18 years of age for expectant mothers 5. Willingness to be followed and deliver at a RAFT center 6. Willingness for postnatal care to be performed at a RAFT center until discharge 7. Completed consults with Pediatric Nephrology, Neonatology, Transplant Surgery, Pediatric surgery, Maternal-Fetal Medicine Specialist, and Licensed Clinical Social Worker and a Genetic Counselor Exclusion Criteria: 1. Cervix less than 2.5 cm in length 2. No significant pathogenic or likely significant pathogenic findings on Karyotype or Microarray 3. Other significant congenital anomalies in the fetus 4. Evidence of chorioamnionitis or abruptio placentae 5. Evidence of rupture of membranes or chorioamniotic separation 6. Evidence of preterm labor 7. Multiple gestation 8. Severe maternal medical condition in pregnancy. 9. Maternal depression as assessed by a Beck Depression Inventory score equal to or greater than 17 that is refractory to treatment 10. Technical limitations precluding amnioinfusion

Study Info

Interventions

Locations Recruiting

Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.